| VP-0001 |
Abraxane® (paclitaxel protein-bound particles) (Intravenous) |
|
| VP-0004 |
Adcetris® (brentuximab vedotin) (Intravenous) |
|
| VP-0007 |
Alimta® (pemetrexed) (Intravenous) |
|
| VP-0008 |
Aloxi® (palonosetron) (Intravenous) |
|
| VP-0014 |
Avastin® (bevacizumab) (Intravenous) |
|
| VP-0036 |
Emend® (fosaprepitant dimeglumine) (Intravenous) |
|
| VP-0038 |
Erbitux® (cetuximab) (Intravenous) |
|
| VP-0043 |
Faslodex® (fulvestrant) (Intramuscular) |
|
| VP-0057 |
Herceptin® (trastuzumab) (Intravenous) |
|
| VP-0071 |
Immune Globulins (immunoglobulin) (Intravenous) |
|
| VP-0092 |
Kadcyla® (ado-trastuzumab emtansine) (Intravenous) |
|
| VP-0096 |
Perjeta® (pertuzumab) (Intravenous) |
|
| VP-0100 |
Provenge® (sipuleucel-T) (Intravenous) |
|
| VP-0109 |
Rituxan® (rituximab) (Intravenous) |
|
| VP-0130 |
Bendamustine (Treanda®; Bendeka™) (Intravenous) |
|
| VP-0136 |
Vectibix® (panitumumab) (Intravenous) |
|
| VP-0137 |
Velcade® (bortezomib) (Intravenous/Subcutaneous) |
|
| VP-0148 |
Yervoy™ (ipilimumab) (Intravenous) |
|
| VP-0157 |
Kyprolis® (carfilzomib) (Intravenous) |
|
| VP-0161 |
Zaltrap® (ziv-aflibercept) (Intravenous) |
|
| VP-0184 |
Gazyva (obinutuzumab) (Intravenous) |
|
| VP-0199 |
Cyramza™ (ramucirumab) (Intravenous) |
|
| VP-0208 |
Arzerra® (ofatumumab) (Intravenous) |
|
| VP-0225 |
Blincyto® (blinatumomab) (Intravenous) |
|
| VP-0226 |
Opdivo® (nivolumab) (Intravenous) |
|
| VP-0234 |
Colony Stimulating Factors: Neulasta® (pegfilgrastim) (Subcutaneous) |
|
| VP-0235 |
Colony Stimulating Factors: Neupogen® (filgrastim) (Subcutaneous/Intravenous) |
|
| VP-0236 |
Colony Stimulating Factors: Granix® (tbo-filgrastim) (Subcutaneous/Intravenous) |
|
| VP-0237 |
Colony Stimulating Factors: Leukine® (sargramostim) (Subcutaneous/Intravenous) |
|
| VP-0245 |
Colony Stimulating Factors: Zarxio™ (filgrastim-sndz) (Subcutaneous/Intravenous) |
|
| VP-0257 |
Yondelis® (trabectedin) (Intravenous) |
|
| VP-0268 |
Empliciti™ (elotuzumab) (Intravenous) |
|
| VP-0278 |
Tecentriq™ (atezolizumab) (Intravenous) |
|
| VP-0283 |
Sustol® (granisetron extended-release) (Subcutaneous) |
|
| VP-0295 |
Bavencio® (avelumab) (Intravenous) |
|
| VP-0301 |
Imfinzi™ (durvalumab) (Intravenous) |
|
| VP-0317 |
Besponsa (inotuzumab ozogamicin) (Intravenous) |
|
| VP-0319 |
Kymriah (tisagenlecleucel) (Intravenous) |
|
| VP-0320 |
Mylotarg (gemtuzumab ozogamicin) (Intravenous) |
|
| VP-0322 |
Rituxan Hycela™ (rituximab and hyaluronidase human) (Subcutaneous) |
|
| VP-0333 |
Yescarta™ (axicabtagene ciloleucel) (Intravenous) |
|
| VP-0336 |
Cinvanti™ (aprepitant) (Intravenous) |
|
| VP-0351 |
Bortezomib* (Intravenous Only) |
|
| VP-0363 |
Akynzeo® (fosnetupitant/palonosetron) (Intravenous) |
|
| VP-0370 |
Colony Stimulating Factors: Fulphila™ (pegfilgrastim-jmdb) (Subcutaneous) |
|
| VP-0375 |
Colony Stimulating Factors: Nivestym™ (filgrastim-aafi) (Subcutaneous/Intravenous) |
|
| VP-0409 |
Colony Stimulating Factors: Udenyca™ (pegfilgrastim-cbqv) (Subcutaneous) |
|
| VP-0415 |
Truxima® (rituximab-abbs) (Intravenous) |
|
| VP-0422 |
Bendamustine (bendamustine ready-to-dilute) (Intravenous) (Belrapzo™) |
|
| VP-0431 |
Herzuma® (trastuzumab-pkrb) (Intravenous) |
|
| VP-0432 |
Ontruzant® (trastuzumab-dttb) (Intravenous) |
|
| VP-0449 |
Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) (Subcutaneous) |
|
| VP-0451 |
Trazimera™ (trastuzumab-qyyp) (Intravenous) |
|
| VP-0461 |
Mvasi™ (bevacizumab-awwb) (Intravenous) |
|
| VP-0462 |
Ogivri™ (trastuzumab-dkst) (Intravenous) |
|
| VP-0482 |
Polivy™ (polatuzumab vedotin-piiq) (Intravenous) |
|
| VP-0483 |
Kanjinti™ (trastuzumab-anns) (Intravenous) |
|
| VP-0484 |
Zirabev™ (bevacizumab-bvzr) (Intravenous) |
|
| VP-0486 |
Ruxience® (rituximab-pvvr) |
|
